Investment Rating - The report maintains an "Outperform the Market" investment rating for the insurance industry [1][4]. Core Insights - The release of the Commercial Health Insurance Innovative Drug Directory marks a significant step for commercial health insurance in the innovative drug payment sector, creating a "second battlefield" that complements the basic medical insurance directory [2][13]. - The new policy alleviates the long-standing conflict between cost control pressures in medical insurance and the innovation demands of pharmaceutical companies, injecting momentum into the healthy development of China's innovative drug industry [2][13]. - The unified directory standardizes fragmented special drug demand and centralizes payment data, providing a reusable "public infrastructure" for the industry, enabling insurance companies to sustainably manage risks in the innovative drug sector for the first time [2][13]. Summary by Sections Policy Positioning - The introduction of the innovative drug directory clarifies the boundaries between basic medical insurance and commercial health insurance in the innovative drug payment field, allowing commercial insurance to play a supplementary role in the multi-tiered medical security system [3][10]. Market Size and Growth - In 2024, the commercial health insurance premium income reached 977.3 billion yuan, nearing the scale of resident medical insurance funding for the same year. However, the total payment for innovative drugs by commercial health insurance was only 7.4 billion yuan, representing a mere 5.3% of the 140 billion yuan innovative drug market [3][6]. Payment Mechanism - The directory employs a price negotiation mechanism, granting companies greater pricing power, which is beneficial for rapid cost recovery of R&D and encourages innovation in the pharmaceutical sector [6][8]. Liability Side - The implementation of the commercial health insurance directory is expected to clarify the boundaries of medical insurance and commercial insurance, thereby increasing demand for medical insurance products [10]. Asset Side - The directory provides insurance funds with opportunities for deep integration with the medical industry, allowing for a dual approach of "insurance + investment" to achieve excess returns [12][13]. Investment Recommendations - The report suggests focusing on companies with differentiated advantages in the health insurance sector, such as China Property & Casualty Insurance, Ping An Insurance, China Taiping Insurance, and ZhongAn Online [2][13].

Core Insights - The National Healthcare Security Administration has added a commercial health insurance innovative drug directory, including 19 new drugs, supplementing the traditional medical insurance drug list [1][3]. Group 1: Commercial Health Insurance Innovative Drug Directory - The commercial health insurance innovative drug directory serves as an effective supplement to basic medical insurance, allowing patients access to innovative drugs not covered by basic insurance [3]. - The drugs included in the commercial health insurance innovative drug directory do not affect the self-pay rate of basic medical insurance and are not included in centralized procurement monitoring indicators or disease-based payment ranges [5]. - The directory focuses on highly innovative drugs with significant clinical value and benefits for patients that exceed the coverage of basic medical insurance [7]. Group 2: Specific Drugs and Conditions - The 19 drugs encompass CAR-T therapies and immunotherapy drugs for liver cancer, which is prevalent in China, providing more treatment options for cancer [9]. - The directory also includes drugs for rare diseases such as Gaucher's disease and short bowel syndrome, as well as treatments for Alzheimer's disease, marking their first inclusion in the commercial insurance directory [9]. Group 3: Market Impact and Growth - In 2024, the original insurance premium income for commercial health insurance in China is projected to reach 977.3 billion yuan, reflecting an 8.2% year-on-year growth, nearing the total funding level of resident medical insurance for that year [11]. - The backing of the state for commercial health insurance through the innovative drug directory is expected to attract more participants, effectively reducing customer acquisition costs for commercial health insurance [13]. - The innovative drug directory allows basic medical insurance to maintain a universal coverage baseline while commercial insurance takes on high-value innovative drugs, encouraging companies to focus more on clinical innovation [15].

Core Insights - The 2025 Innovation Drug High-Quality Development Conference was held in Guangzhou on December 7, where the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog was released [1] - This is the 8th adjustment since the establishment of the National Medical Insurance Administration, with the new catalog set to be implemented nationwide on January 1, 2026 [1] - The adjustment adds 114 new drugs, including 50 first-class innovative drugs, while removing 29 drugs that are either not clinically available or can be replaced by better alternatives [1] - The total number of drugs in the catalog increases to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, with significant improvements in coverage for key areas such as cancer, chronic diseases, mental illnesses, rare diseases, and pediatric medications [1] - Additionally, the National Medical Insurance Administration released the first commercial insurance innovative drug catalog, which includes 19 drugs covering rare diseases, neurodegenerative diseases, other solid tumors/blood tumors, and metabolic diseases [1] Summary by Categories Drug Catalog Adjustments - The new drug catalog will include 114 new drugs, with a focus on innovative treatments [1] - 50 of the newly added drugs are classified as first-class innovative drugs [1] - A total of 29 drugs have been removed from the catalog due to lack of clinical supply or better alternatives [1] Coverage and Focus Areas - The total number of drugs in the catalog has increased to 3,253, enhancing the coverage for critical health areas [1] - Key areas with improved coverage include cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1] Commercial Insurance Developments - The first commercial insurance innovative drug catalog includes 19 drugs targeting specific health conditions [1] - The catalog covers treatments for rare diseases, neurodegenerative diseases, solid tumors, blood tumors, and metabolic disorders [1]